Trials / Completed
CompletedNCT00254540
Study of SU011248 in Patients With Advanced Kidney Cancer
Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SU011248 capsule | 50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2005-11-16
- Last updated
- 2010-02-23
- Results posted
- 2010-02-11
Locations
11 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00254540. Inclusion in this directory is not an endorsement.